

1 February 2022

Treatment of Ovarian Cancer

1. How many patients have been treated for advanced (FIGO Stages III and IV) high-grade ovarian (epithelial ovarian, fallopian tube or primary peritoneal) cancer over the last 3 months? If none, do you refer ovarian cancer patients to another trust, if so which one?

115 patients treated with systemic anti-cancer treatment (SACT)

2. How many ovarian cancer patients (any stage) have been treated in the last 3 months with:

- **Paclitaxel in combination with a platinum-based compound** 38
- **Platinum-based therapy alone (cisplatin or carboplatin)** 0
- **Bevacizumab in combination with paclitaxel and carboplatin** <5
- **Olaparib** 23
- **Olaparib + Bevacizumab** 0
- **Niraparib** 51
- **Rucaparib** <5

3. Of the ovarian cancer patients (any stage) treated over the last 3 months, how many patients:

- **Received HRD (homologous recombination deficiency) testing** 18
- **Received (germline) BRCA testing** 29
- **Tested HRD positive** <5
- **Tested BRCA positive (BRCAm)** <5

4. If data for HRD testing is available, please provide how many HRD positive patients were treated in the last 3 months with:

- **Olaparib**
- **Olaparib + Bevacizumab**
- **Niraparib**
- **Other treatments**

Not Available via RISOH

1 February 2022

5. If data for HRD and BRCA testing is available, please provide how many HRD positive-BRCA positive patients were treated in the last 3 months with:

- **Olaparib**
- **Olaparib + Bevacizumab**
- **Niraparib**
- **Other treatments**

Not Available via RISOH